JAK3i

CAS No. 1918238-72-8

JAK3i( JAK3 inhibitor JAK3i )

Catalog No. M13007 CAS No. 1918238-72-8

JAK3i is a selective, covalent JAK3 kinase inhibitor with IC50 of 0.43 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 662 In Stock
5MG 787 In Stock
10MG 1074 In Stock
25MG 1511 In Stock
50MG 1841 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    JAK3i
  • Note
    Research use only, not for human use.
  • Brief Description
    JAK3i is a selective, covalent JAK3 kinase inhibitor with IC50 of 0.43 nM.
  • Description
    JAK3i is a selective, covalent JAK3 kinase inhibitor with IC50 of 0.43 nM, shows high selectivity (>3,000-fold) against the closely related kinase domains in JAK1, JAK2, or TYK2, displays 1,300-fold, 600-fold, and 50-fold over EGFR, ITK, and BTK respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    JAK3 inhibitor JAK3i
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1918238-72-8
  • Formula Weight
    354.34
  • Molecular Formula
    C18H15FN4O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(C1=CNC2=NC=NC(C3=CC(NC(C=C)=O)=CC=C3F)=C21)OCC
  • Chemical Name
    Ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Smith GA, et al. Nat Chem Biol. 2016 May;12(5):373-9.
molnova catalog
related products
  • WDR5-0103 hydrochlor...

    WDR5-0103 is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM).

  • Oclacitinib

    Oclacitinib(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM.

  • Povorcitinib phospha...

    Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.